In addition to VIP236, Vincerx’s pipeline has a clinical-stage cyclin-dependent kinase-9 (CDK9) inhibitor program, VIP152 2, and two preclinical ADC candidates that exemplify the differentiated ...
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer. In part 2 of ...
Antibody–drug conjugates (ADCs) deliver potent anti-cancer drugs directly to tumor cells by taking advantage of the ability of antibodies to recognize cancer cell receptors. This targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback